ATE171042T1 - Verfahren und zusammensetzungen zur verbesserung der symptome von sepsis - Google Patents

Verfahren und zusammensetzungen zur verbesserung der symptome von sepsis

Info

Publication number
ATE171042T1
ATE171042T1 AT90911485T AT90911485T ATE171042T1 AT E171042 T1 ATE171042 T1 AT E171042T1 AT 90911485 T AT90911485 T AT 90911485T AT 90911485 T AT90911485 T AT 90911485T AT E171042 T1 ATE171042 T1 AT E171042T1
Authority
AT
Austria
Prior art keywords
sepsis
symptoms
compositions
improving
methods
Prior art date
Application number
AT90911485T
Other languages
English (en)
Inventor
Richard Ulevitch
Peter Tobias
Samuel D Wright
John D Mathison
Original Assignee
Scripps Research Inst
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Univ Rockefeller filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE171042T1 publication Critical patent/ATE171042T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Two-Way Televisions, Distribution Of Moving Picture Or The Like (AREA)
AT90911485T 1989-08-01 1990-07-30 Verfahren und zusammensetzungen zur verbesserung der symptome von sepsis ATE171042T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38781789A 1989-08-01 1989-08-01

Publications (1)

Publication Number Publication Date
ATE171042T1 true ATE171042T1 (de) 1998-10-15

Family

ID=23531466

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90911485T ATE171042T1 (de) 1989-08-01 1990-07-30 Verfahren und zusammensetzungen zur verbesserung der symptome von sepsis

Country Status (14)

Country Link
US (4) US5730980A (de)
EP (1) EP0485430B1 (de)
JP (1) JP2744130B2 (de)
AT (1) ATE171042T1 (de)
AU (1) AU645515B2 (de)
CA (1) CA2022429C (de)
DE (1) DE69032662T2 (de)
DK (1) DK0485430T3 (de)
ES (1) ES2120948T3 (de)
FI (1) FI920450A0 (de)
GR (1) GR1003164B (de)
IE (1) IE902770A1 (de)
PT (1) PT94869B (de)
WO (1) WO1991001639A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE171042T1 (de) * 1989-08-01 1998-10-15 Scripps Research Inst Verfahren und zusammensetzungen zur verbesserung der symptome von sepsis
DE4029227A1 (de) * 1990-09-14 1992-03-19 Imtox Gmbh Arzneimittel enthaltend cd14
WO1993019772A1 (en) * 1992-04-06 1993-10-14 North Shore University Hospital Research Corporation A novel therapy for treating sepsis using a soluble form of recombinant cd14 myelomonocytic antigen
US5820858A (en) * 1993-05-28 1998-10-13 The Scripps Research Institute Methods and compositions for inhibiting CD14 mediated cell activation
US5731415A (en) 1993-06-17 1998-03-24 Xoma Corporation Lipopolysaccharide binding protein derivatives
US5484705A (en) * 1994-01-24 1996-01-16 Xoma Corporation Method for quantifying lipopolysaccharide binding protein
US5891618A (en) 1994-01-24 1999-04-06 Xoma Corporation Method for quantifying LBP in body fluids
ES2255708T3 (es) 1994-09-16 2006-07-01 The Scripps Research Institute Uso de anticuerpos para bloquear los efectos de las bacterias gram-positivas y las micobacterias.
JPH10512142A (ja) * 1994-12-30 1998-11-24 アムジエン・インコーポレーテツド 抗炎症性ｃｄ１４ポリペプチド
US5766593A (en) * 1994-12-30 1998-06-16 Amgen Inc. Anti-inflammatory CD14 peptides
AU5688596A (en) * 1995-04-13 1996-10-30 Deutsche Om Arzneimittel Gmbh Anti-cd14 antibodies for use in the induction of il-10 secre tion
AU6392996A (en) * 1995-06-19 1997-01-15 Sanna M. Goyert A method for inhibiting bacteremia and bacterial dissemination
AU735058B2 (en) 1996-05-10 2001-06-28 Xoma Corporation Therapeutic uses of BPI protein products for human meningococcemia
ATE234111T1 (de) * 1996-05-23 2003-03-15 Xoma Technology Ltd Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
US6093693A (en) * 1996-11-18 2000-07-25 The Wellesley Hospital Foundation B cell activation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US5990082A (en) * 1997-10-22 1999-11-23 Xoma Corporation Uses of lipopolysaccharide binding protein
PL194240B1 (pl) * 1998-02-07 2007-05-31 British Biotech Pharm Zastosowanie pochodnych N-formylohydroksyloaminy i amidowa pochodna N-formylohydroksyloaminy
BR9910725A (pt) * 1998-05-27 2001-01-30 Gemma Biotechnology Ltd Indução de proteìnas e peptìdeos antibióticos por proteìnas lait/s cd14
US6974698B1 (en) * 1999-01-15 2005-12-13 The United States Of America As Represented By The Department Of Health And Human Services Methods for delivering biologically active molecules into cells
US6916628B1 (en) 1999-09-17 2005-07-12 Mochida Pharmaceutical Co., Ltd. Method for the measurement of soluble CD14 proteins separately
EP1336620A4 (de) * 2000-11-22 2004-11-17 Mochida Pharm Co Ltd Monoklonaler, die cd14/tlr-bindung hemmender anti-cd14-antikörper
AU2002221099A1 (en) * 2000-12-08 2002-06-18 Takeda Chemical Industries Ltd. Combination drugs
AU2003253621A1 (en) * 2002-06-14 2003-12-31 Centocor, Inc. Modified "s" antibodies
EP2266606B1 (de) * 2003-05-15 2014-09-10 Genentech, Inc. Verfahren und Zubereitungen zur Prävention und Behandlung von Blutvergiftung
WO2006093794A1 (en) * 2005-02-28 2006-09-08 Centocor, Inc. Heterodimeric protein binding compositions
US7696211B2 (en) * 2005-04-29 2010-04-13 Wilson Constance N Methods and pharmaceutical compositions for treating sepsis
CN103665168A (zh) 2005-06-03 2014-03-26 持田制药株式会社 抗cd14抗体融合蛋白质
US20170107294A1 (en) * 2014-03-21 2017-04-20 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
AU2018255489B2 (en) 2017-04-21 2024-06-13 Implicit Bioscience Limited CD 14 antagonist antibodies for treating neurodegenerative diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057598A (en) * 1983-05-06 1991-10-15 Centocor, Inc. Monoclonal antibodies reactive with endotoxin core
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
US4834976A (en) * 1986-07-03 1989-05-30 Genetic Systems Corporation Monoclonal antibodies to pseudomonas aeruginosa flagella
ATE171042T1 (de) * 1989-08-01 1998-10-15 Scripps Research Inst Verfahren und zusammensetzungen zur verbesserung der symptome von sepsis

Also Published As

Publication number Publication date
EP0485430A1 (de) 1992-05-20
AU645515B2 (en) 1994-01-20
FI920450A7 (fi) 1992-01-31
CA2022429A1 (en) 1991-02-02
DE69032662D1 (de) 1998-10-22
PT94869B (pt) 1997-04-30
US5730980A (en) 1998-03-24
US6297049B1 (en) 2001-10-02
EP0485430A4 (en) 1993-03-03
US6045795A (en) 2000-04-04
WO1991001639A1 (en) 1991-02-21
ES2120948T3 (es) 1998-11-16
DK0485430T3 (da) 1999-06-14
US6495332B2 (en) 2002-12-17
EP0485430B1 (de) 1998-09-16
PT94869A (pt) 1991-04-18
GR1003164B (el) 1999-07-05
FI920450A0 (fi) 1992-01-31
AU6146190A (en) 1991-03-11
GR900100582A (el) 1991-12-30
JP2744130B2 (ja) 1998-04-28
US20020034509A1 (en) 2002-03-21
CA2022429C (en) 1998-12-01
JPH05501399A (ja) 1993-03-18
IE902770A1 (en) 1991-02-27
DE69032662T2 (de) 1999-03-11

Similar Documents

Publication Publication Date Title
DE69032662D1 (de) Verfahren und zusammensetzungen zur verbesserung der symptome von sepsis
DE69230789D1 (de) Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten
EP0938505A4 (de) Monoklonale antikörper gegen endoglin und ihre verwendung in der antiangiogenen therapie
DE69724451D1 (de) Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
DE69327582D1 (de) Methoden zur Behandlung von Interleukin- 1 und - Tumor - Nekrose - Faktor - verursachten Krankheiten
ATE196849T1 (de) Verfahren zur behandlung von multiplesklerose
UA26403A (uk) Похідhі n-заміщеhого 4-феhіл-4-піперидиhкарбоксаміду та їх фармацевтичhо прийhятhі солі, що проявляють аhестезувальhу та аhальгезувальhу дію, спосіб їх одержаhhя та фармацевтичhа композиція
NO307645B1 (no) Anvendelse av probenecid i kombinasjon med en eksitatorisk aminosyre-antagonist for fremstilling av et farmasøytisk preparat
ATE138567T1 (de) Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen
DE69511245D1 (de) Zusammensetzung und verfahren zur verhinderung und behandlung von entzündung mit immunoglobin a
DE69534601D1 (de) Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien
DE69327248D1 (de) Verfahren zur behandlung des symptomenkomplexes des prämenstruellen syndroms mit vitamin d oder vitamin d und calcium
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
ATE187648T1 (de) Zusammensetzungen enthaltend lipoprotein- associated-coagulation-inhibitor (laci) zur herstellung eines medikaments zur behandlung von akuten oder chronischen enzündungen
ATE136222T1 (de) Heilmittel und verfahren zur inhibierung der vaskularisierung von tumoren
EA200200518A1 (ru) Способ и композиция для лечения заболеваний легких
AU570062B2 (en) Pharmaceutical compositions derived from beeswax
ATE218334T1 (de) Verwendung von gabapentin in der behandlung vonangst - und panikstörungen
FR2303558A1 (fr) Preparation therapeutique pour traiter l'infection sous forme de pneumonie hemorragique du vison et de mastite bovine causees par la pseudomonas aeruginosa
DE69123580D1 (de) Verwendung von antagonisten des plättchen-aktivierenden faktors bei pruritus
FR2672888B1 (fr) Nouvelles urees et thiourees, leur preparation et leur application en therapeutique.
DE69127346D1 (de) Behandlung thrombotischer ereignisse

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time